The global market for Osteoporosis Therapeutics was estimated at US$12.7 Billion in 2023, and is projected to reach US$15.5 Billion by 2030, growing at a CAGR of 2.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. ![Global Osteoporosis Therapeutics Market]( "Global Osteoporosis Therapeutics Market")
The growth in the osteoporosis therapeutics market is driven by several factors, including the increasing global elderly population, rising prevalence of osteoporosis, advancements in therapeutic options, and growing awareness of the disease. As the global population ages, the incidence of osteoporosis and resultant fractures is expected to rise, driving demand for effective treatment solutions. Advances in pharmaceuticals and biotechnology have led to the development of newer, more effective drugs with fewer side effects, enhancing patient outcomes and compliance. Additionally, there is a growing emphasis on early diagnosis and prevention, supported by improvements in diagnostic technologies and screening practices, which further stimulate the market. Increased public and medical community awareness about osteoporosis and its impact on quality of life has also helped to drive the market, as has the expansion of healthcare infrastructure and insurance coverage in emerging economies. These dynamics suggest that the osteoporosis therapeutics market will continue to expand, driven by both an urgent need for effective management of osteoporosis and ongoing improvements in therapeutic practices and products.
The growth in the osteoporosis therapeutics market is driven by several factors, including the increasing global elderly population, rising prevalence of osteoporosis, advancements in therapeutic options, and growing awareness of the disease. As the global population ages, the incidence of osteoporosis and resultant fractures is expected to rise, driving demand for effective treatment solutions. Advances in pharmaceuticals and biotechnology have led to the development of newer, more effective drugs with fewer side effects, enhancing patient outcomes and compliance. Additionally, there is a growing emphasis on early diagnosis and prevention, supported by improvements in diagnostic technologies and screening practices, which further stimulate the market. Increased public and medical community awareness about osteoporosis and its impact on quality of life has also helped to drive the market, as has the expansion of healthcare infrastructure and insurance coverage in emerging economies. These dynamics suggest that the osteoporosis therapeutics market will continue to expand, driven by both an urgent need for effective management of osteoporosis and ongoing improvements in therapeutic practices and products.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Bisphosphonates segment, which is expected to reach US$8.1 Billion by 2030 with a CAGR of a 3.1%. The Parathyroid Hormone Therapy segment is also set to grow at 2.3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $5.2 Billion in 2023, and China, forecasted to grow at an impressive 5.3% CAGR to reach $900.1 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Osteoporosis Therapeutics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Osteoporosis Therapeutics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Osteoporosis Therapeutics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Amgen, Inc., Asahi Kasei Pharma Corporation, Bone Biologics Corp., and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 53 Featured):
- Amgen, Inc.
- Asahi Kasei Pharma Corporation
- Bone Biologics Corp.
- Novartis AG
- Pfizer, Inc.
- Taisho Pharmaceutical Co., Ltd.
- Teijin Ltd.
- Transcenta
- Uni-Bio Science Group Ltd.
- Viking Therapeutics
- Zydus Lifesciences Limited
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY
III. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- A Prelude to Osteoporosis
- Growing Geriatric Population and Rising Incidence of Osteoporosis Drive the Global Osteoporosis Market
- Developed Regions Dominate the Global Market, Developing to Witness Fastest Growth
- Bisphosphonates - The Largest Category of Drugs for Treating Osteoporosis
- Approved Drugs for Treatment of Osteoporosis
- Select Recent Osteoporosis Drug Approvals
- Osteoporosis Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
- Amgen, Inc. (US)
- Chugai Pharmaceutical Co., Ltd. (Japan)
- Daiichi Sankyo Co., Ltd. (Japan)
- Eisai Co., Ltd. (Japan)
- Eli Lilly and Company (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Merck & Co. Inc. (USA)
- Novartis International AG (Switzerland)
- Pfizer, Inc. (US)
- Radius Health, Inc. (USA)
3. MARKET TRENDS & DRIVERS
- Growing Incidence of Osteoporosis Augurs Well for Osteoporosis Therapeutics
- Osteoporosis - Factsheet
- Osteoporosis in Men
- Rising Geriatric Population and the Associated Bone Health Issues to Drive Market Gains
- Global Population of 65+ Individuals (In 000s) by Region for the Years 2015, 2020 & 2025
- Rising Prevalence of Osteoporosis in Post-menopausal Women Propels Market Growth
- Changing Lifestyle Impacting Bone Health
- Recommended Daily Intake of Calcium and Vitamin D
- Increasing Awareness Related to Osteoporosis Care
- New Product Launches Foster Market Growth
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Osteoporosis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 3: World Historic Review for Osteoporosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 4: World 16-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 6: World Historic Review for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 7: World 16-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 9: World Historic Review for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 10: World 16-Year Perspective for Parathyroid Hormone Therapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 12: World Historic Review for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 13: World 16-Year Perspective for Calcitonin by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 15: World Historic Review for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 16: World 16-Year Perspective for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Rank Ligand Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 18: World Historic Review for Rank Ligand Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 19: World 16-Year Perspective for Rank Ligand Inhibitors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 21: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 22: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 24: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 25: World 16-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 26: World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 27: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 28: World 16-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
UNITED STATES
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 29: USA Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 30: USA Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 31: USA 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
- TABLE 32: USA Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 33: USA Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 34: USA 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030
CANADA
- TABLE 35: Canada Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 36: Canada Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 37: Canada 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
- TABLE 38: Canada Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 39: Canada Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 40: Canada 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030
JAPAN
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 41: Japan Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 42: Japan Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 43: Japan 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
- TABLE 44: Japan Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 45: Japan Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 46: Japan 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030
CHINA
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 47: China Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 48: China Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 49: China 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
- TABLE 50: China Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 51: China Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 52: China 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030
EUROPE
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 53: Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 54: Europe Historic Review for Osteoporosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 55: Europe 16-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 56: Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 57: Europe Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 58: Europe 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
- TABLE 59: Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 60: Europe Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 61: Europe 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030
FRANCE
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 62: France Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 63: France Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 64: France 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
- TABLE 65: France Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 66: France Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 67: France 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030
GERMANY
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 68: Germany Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 69: Germany Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 70: Germany 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
- TABLE 71: Germany Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 72: Germany Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 73: Germany 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030
ITALY
- TABLE 74: Italy Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 75: Italy Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 76: Italy 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
- TABLE 77: Italy Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 78: Italy Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 79: Italy 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 80: UK Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 81: UK Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 82: UK 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
- TABLE 83: UK Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 84: UK Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 85: UK 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030
REST OF EUROPE
- TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 87: Rest of Europe Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 88: Rest of Europe 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
- TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 90: Rest of Europe Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 91: Rest of Europe 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 93: Asia-Pacific Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 94: Asia-Pacific 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
- TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 96: Asia-Pacific Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 97: Asia-Pacific 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030
REST OF WORLD
- TABLE 98: Rest of World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 99: Rest of World Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 100: Rest of World 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
- TABLE 101: Rest of World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 102: Rest of World Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 103: Rest of World 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030
Companies Mentioned
- Amgen, Inc.
- Asahi Kasei Pharma Corporation
- Bone Biologics Corp.
- Novartis AG
- Pfizer, Inc.
- Taisho Pharmaceutical Co., Ltd.
- Teijin Ltd.
- Transcenta
- Uni-Bio Science Group Ltd.
- Viking Therapeutics
- Zydus Lifesciences Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 340 |
| Published | December 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 12.7 Billion |
| Forecasted Market Value ( USD | $ 15.5 Billion |
| Compound Annual Growth Rate | 2.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
